A new study by Dr Ruth Dobson and colleagues at Queen Mary University London found that people with MS had higher levels of vitamin D than people without MS, because they were more likely to take a supplement.
The National Institute for Health and Care Excellence (NICE) has provisionally decided not to recommend ozanimod for people with relapsing MS on the NHS. This is the first stage of the approval process around this new MS treatment.
Siponimod (Mayzent) has been approved on the NHS as the first ever oral treatment for people living with active secondary progressive MS (SPMS) in England and Wales. The drug was recommended for use in Scotland a few days ago, and we expect a decision to follow in Northern Ireland in the coming months.
Siponimod (Mayzent) has been approved by the Scottish Medicine Consortium (SMC) for people with active secondary progressive multiple sclerosis (SPMS), meaning those who experience relapses or have evidence of inflammation on MRI scans.